Tradewinds Capital Management LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Tradewinds Capital Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 6.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,398 shares of the company’s stock after buying an additional 423 shares during the period. Johnson & Johnson accounts for about 0.4% of Tradewinds Capital Management LLC’s investment portfolio, making the stock its 29th biggest position. Tradewinds Capital Management LLC’s holdings in Johnson & Johnson were worth $957,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 0.7% during the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after buying an additional 1,627,370 shares during the last quarter. Phocas Financial Corp. grew its stake in shares of Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $174,342,000 after buying an additional 125,161,066 shares during the last quarter. Northern Trust Corp grew its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock valued at $4,910,381,000 after buying an additional 313,073 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after buying an additional 2,204,757 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock valued at $2,784,913,000 after buying an additional 122,033 shares during the last quarter. Institutional investors own 72.05% of the company’s stock.

NYSE:JNJ traded down $8.47 during midday trading on Friday, hitting $127.70. The stock had a trading volume of 25,279,318 shares, compared to its average volume of 7,754,786. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a market capitalization of $359.38 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.30 and a beta of 0.69. The stock has a 50-day moving average of $130.45 and a 200 day moving average of $134.76. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. The company had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the prior year, the firm earned $2.05 earnings per share. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.98%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

A number of research firms have recently commented on JNJ. Bank of America reaffirmed a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday. Morgan Stanley reissued an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Raymond James dropped their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective on the stock in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average price target of $151.18.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.